West Chester, PA, United States of America

John A Gruner

This inventor holds 1 USPTO granted patent. Top assignee: Cephalon, Inc.. Active years: 2008.


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2008

Loading Chart...
1 patent (USPTO):Explore Patents

Title: John A. Gruner: Innovator in Pharmaceutical Chemistry

Introduction

John A. Gruner is a notable inventor based in West Chester, PA (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on tricyclic aromatic and bis-phenyl sulfinyl derivatives. His research has the potential to impact the treatment of various diseases.

Latest Patents

Gruner holds 1 patent for his invention titled "Tricyclic aromatic and bis-phenyl sulfinyl derivatives." This patent provides compounds of a specific structure, which includes pharmaceutical compositions and methods for treating diseases. His work exemplifies the intersection of chemistry and medicine, showcasing the importance of innovative solutions in healthcare.

Career Highlights

John A. Gruner is associated with Cephalon, Inc., a company known for its focus on developing innovative therapies for various medical conditions. His role at Cephalon has allowed him to collaborate with other talented professionals in the field, further enhancing his contributions to pharmaceutical research.

Collaborations

Throughout his career, Gruner has worked alongside esteemed colleagues such as Edward R. Bacon and Sankar Chatterjee. These collaborations have fostered a rich environment for innovation and have led to advancements in their shared field of expertise.

Conclusion

John A. Gruner's work in pharmaceutical chemistry highlights the importance of innovation in developing new treatments. His contributions, particularly through his patent, demonstrate the potential for scientific advancements to improve healthcare outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…